These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12566911)

  • 21. A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
    Rinaldi DA; Lormand NA; Brierre JE; Cole JL; Stagg MP; Fontenot MF; Buller EJ; Rainey JM
    Am J Clin Oncol; 2000 Feb; 23(1):78-82. PubMed ID: 10683085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
    Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
    Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    Reni M; Cereda S; Mazza E; Passoni P; Nicoletti R; Balzano G; Zerbi A; Arcidiacono PG; Staudacher C; Di Carlo V
    Am J Clin Oncol; 2008 Apr; 31(2):145-50. PubMed ID: 18391598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of metastatic pancreatic cancer with a combination of gemcitabine and 5-fluorouracil: a single center phase II study.
    Kanat O; Evrensel T; Kurt E; Demiray M; Gonullu G; Arslan M; Manavoglu O
    Tumori; 2004; 90(2):192-5. PubMed ID: 15237581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
    J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
    Takamori H; Kanemitsu K; Tsuji T; Tanaka H; Chikamoto A; Nakahara O; Hiraoka T; Ikeda O; Kudo K; Imuta M; Yamashita Y
    Pancreas; 2005 Apr; 30(3):223-6. PubMed ID: 15782098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
    Kim H; Park JH; Shin SJ; Kim MJ; Bang SJ; Park NH; Nah YW; Nam CW; Joo KR; Min YJ
    Chemotherapy; 2008; 54(1):54-62. PubMed ID: 18073472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
    Berlin JD; Catalano P; Thomas JP; Kugler JW; Haller DG; Benson AB
    J Clin Oncol; 2002 Aug; 20(15):3270-5. PubMed ID: 12149301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
    Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E;
    Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
    Shan YS; Lin PW
    Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
    Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
    Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization.
    Miyanishi K; Ishiwatari H; Hayashi T; Takahashi M; Kawano Y; Takada K; Ihara H; Okuda T; Takanashi K; Takahashi S; Sato Y; Matsunaga T; Homma H; Kato J; Niitsu Y
    Jpn J Clin Oncol; 2008 Apr; 38(4):268-74. PubMed ID: 18375446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
    Kobayashi N; Shimamura T; Tokuhisa M; Goto A; Endo I; Ichikawa Y
    Medicine (Baltimore); 2017 May; 96(19):e6769. PubMed ID: 28489753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
    Santasusana JM; García López JL; García JJ; Carbonero AI; Plazas JG; Rovira PS; Martos CF; Guzmán MC; Jericó JF; Delgado FJ; Espinosa JC; Muñoz ML; Aguilar EA; Valera JS; García Ribas I; Mena AC
    Clin Transl Oncol; 2005 Dec; 7(11):493-8. PubMed ID: 16373060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
    Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
    Marti JL; Hochster HS; Hiotis SP; Donahue B; Ryan T; Newman E
    Ann Surg Oncol; 2008 Dec; 15(12):3521-31. PubMed ID: 18830756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.